Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Resveratrol-loaded chitosan nanoparticles and adipose-derived stem cell-conditioned medium for liver protection against ischemia-reperfusion injury.

Chen L., Shi J., Jalili S.

Animal Study on Chronic Inflammation, published in J Mater Sci Mater Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Mater Sci Mater Med (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42154347
DOI
10.1007/s10856-026-07036-z

Abstract (original English)

Ischemia-reperfusion injury (IRI) continues to be a significant obstacle in liver transplantation and often results in graft dysfunction and suboptimal outcomes after transplantation. The current preservation solutions, such as the University of Wisconsin (UW) solution, provide limited protection against oxidative stress, inflammation, and apoptosis. The present study was undertaken to design and test a bioactive preservation solution supplemented with resveratrol-loaded chitosan nanoparticles (Resv-CNPs) and adipose-derived stem cell conditioned medium (ASC-CM) to achieve hepatoprotection during IRI. Resv-CNPs were synthesized using the ionic gelation method and characterized for encapsulation efficiency, release profile, and antioxidant activity. HepG2 cells were exposed to an in vitro IRI model, which involved 24h cold ischemia in UWCM solution followed by 48h reperfusion. Cell viability was evaluated by MTT assay, and ALT, AST, LDH, HMGB1, IL-1β, and IL-6 were measured by ELISA. An in vivo rat model was used to validate the hepatic preservation effect after 24h of cold storage in different solutions. Histopathological changes were assessed by H&E staining and Suzuki scoring. Resv-CNPs had an encapsulation efficiency of 46.21±7.12%, and it showed a biphasic release pattern. The drug release from nanoparticles could provide sustained release of resveratrol for up to 72h. Free

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research